Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

NNRX Pharmaceuticals, Inc.

EconomyAI buildoutMarket MapFundsWatchlist
Log in
N

NRX Pharmaceuticals, Inc.

$3.32Close · Sep 22, 2026
  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Burn Rate
  • Similar companies
  • News
  • Insider Transactions
Loading financials
Income statement waterfall. Revenue $1.1M. Net result −$16.52M. A thin axis line marks the loss-zone boundary.

Income statement waterfall. Green diagonal stripes add to the running result, red diagonal stripes subtract from it, and a thin axis line marks the loss-zone boundary.

  • Revenue: $1.1M. Running result $1.1M. Procedures: $230K. Therapy: $871K.
  • Cost of revenue: −$675K. Running result $426K.
  • Gross profit: $426K. Running result $426K.
  • Research and development: −$2.12M. Running result −$1.69M.
  • Selling, general and administrative: −$4.75M. Running result −$6.44M.
  • Depreciation and amortization: −$66K. Running result −$6.5M.
  • Settlement expense (income): −$4K. Running result −$6.51M.
  • Operating income: −$6.51M. Running result −$6.51M.
  • Other expense: −$10.02M. Running result −$16.52M.
  • Pre-tax loss: −$16.52M. Running result −$16.52M.
  • Income tax benefit: $0. Running result −$16.52M.
  • Net loss: −$16.52M. Running result −$16.52M.